NEW YORK, April 29, 2016 – NYSE MKT LLC (“NYSE MKT” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Tianyin Pharmaceuticals Co., Inc. (the "Company") — ticker symbol TPI —from the Exchange. Trading in the Company’s common stock will be suspended immediately after the close of trading on the NYSE MKT on April 29, 2016.

NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Sections 134 and 1101 of the NYSE MKT Company Guide.  NYSE Regulation notes that there is uncertainty as to when the Company will be able to complete its Form 10-K for the fiscal year ended June 30, 2015 and subsequent Form 10-Q filings for the periods ended September 30, 2015 and December 31, 2015.

The Company has a right to a review of staff’s determination to delist the common stock by a committee of the Board of Directors of the Exchange. The NYSE MKT will apply to the Securities and Exchange Commission to delist the Company’s common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Company Contact:

Jianguo Niu

E-mail: 261088874@qq.com
Tel: +86-13458589222